COVID-19 tracker: Big buyers turn down more Moderna dosesnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: U.S. owes Pfizer $5B for Paxlovid pills; Fourth mRNA dose provides short duration of protectionnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: Full FDA nod did little to spark uptake of Pfizer shot; Antiviral pills plentiful in NYnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: Thailand green lights Novavax, Serum Institute’s shotnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: Japan cancels part of AZ vaccine order; Veru touts positive drug datanews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: Ocugen, working on Bharat’s troubled shot Covaxin, hits clinical snagnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: Pfizer could have variant-tweaked shot ready by fall; Serum CEO says India vaccines are better than mRNAnews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: Pfizer, BioNTech unveil positive booster data in kids 5 to 11news2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
COVID-19 tracker: Japan cancels part of AZ vaccine ordernews2022-01-04T14:42:10+00:00January 4th, 2022|Fierce Pharma|
WuXi’s Shanghai facility gets FDA nod in first preapproval inspectionnews2022-01-04T14:39:37+00:00January 4th, 2022|Fierce Pharma|
